Physician profile
Justin W Case
NPI 1609044015
$41,109.33
in general payments reported to CMS, 2019-2025
33 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $4,835 · 2021: $5,679 · 2022: $3,419 · 2023: $2,003 · 2024: $2,282 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $5,460 · Travel and Lodging: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,565.00 |
| Food and Beverage | $5,460.43 |
| Travel and Lodging | $1,499.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21,302.93 | 2024-2025 | Voquezna |
| Abbvie INC. | $14,152.96 | 2019-2025 | Rinvoq, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,687.09 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $709.03 | 2020-2023 | Spyglass |
| Takeda Pharmaceuticals U.S.A., INC. | $548.69 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Endogastric Solutions, INC | $401.83 | 2022-2024 | Esophyx |
| Janssen Biotech, INC. | $376.66 | 2019-2025 | Stelara, Tremfya, Simponi |
| Janssen Scientific Affairs, LLC | $257.87 | 2023 | Stelara |
| Genzyme Corporation | $221.69 | 2022-2025 | |
| Madrigal Pharmaceuticals | $200.69 | 2024-2025 | Resmetirom, Rezdiffra |
| Qol Medical, LLC | $182.04 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $170.36 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $94.67 | 2019-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $82.95 | 2020-2024 | |
| Olympus America INC. | $77.05 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $64.12 | 2021-2022 | |
| Romark Laboratories, Lc | $63.93 | 2019-2020 | |
| Redhill Biopharma INC. | $52.22 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.93 | 2019-2024 | Dificid |
| Ardelyx, INC. | $50.90 | 2023-2024 | Ibsrela |
| Sandoz INC. | $44.86 | 2023-2024 | Hyrimoz |
| Celgene Corporation | $40.81 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $40.53 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $36.50 | 2023 | Dupixent |
| Covidien LP | $35.64 | 2020 | |
| Aimmune Therapeutics, INC. | $35.51 | 2024-2025 | Zenpep |
| Pfizer INC. | $34.66 | 2020-2022 | |
| Medtronic, INC. | $22.03 | 2023 | Endoflip |
| Braintree Laboratories, INC. | $18.15 | 2025 | Suflave |
| Axonics, INC. | $16.30 | 2023 | Axonics |
| Astrazeneca Pharmaceuticals LP | $12.54 | 2019 | |
| Ethicon US, LLC | $11.37 | 2019 | |
| Allergan, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.